Latest News

The Jack McGovern Coats' Disease Foundation has announced the initiation of new research to develop the first validated animal model of Coats' Disease, a rare eye disorder that primarily affects children.

A roundup of Ophthalmology Times' H1 2026 refractive coverage shows the field moving toward individualized care through adjustable lens outcomes, AI-assisted planning, and refined pediatric myopia monitoring.

Approach centers on pressure-free messaging and optometric education

Patient enrollment is complete in a phase 3 registrational, or pivotal, trial to evaluate OPGx-LCA5, a gene therapy that is under investigation for treating Leber congenital amaurosis type 5-associated inherited retinal disease.

Two investigational pipeline therapies take aim at the root causes of dry eye disease

Noha Ekdawi, MD, FAAP, explains why pediatric myopia demands individualized, progression-based management. She details how they sequence spectacle defocus lenses, low-dose atropine, and specialty contacts; drive long-term adherence; and frame lifetime risk for parents without causing alarm.

Waste, cost, and carbon are converging to reshape how cataract centers choose instruments.

Ahead of his November 10, 2026, start date, the incoming Duke ophthalmology chair shares his vision for research, training, and the integration of AI and data science.

Sight Sciences' newest MIGS device gains FDA clearance for single-pass canaloplasty and trabeculotomy in open-angle glaucoma.

Harrow will acquire Tyrvaya, the only FDA-approved nasal spray for dry eye disease, from Viatris for up to $100 million, complementing its cyclosporine product Vevye.

Private practice fellowships sharpen cataract and refractive skills with high volume, new tech, and hands-on practice management mentorship.

This article discusses the current treatments being investigated during the first half of 2026.

Wet AMD gains a new FDA-approved therapy as retina, glaucoma, and dry eye pipelines surge—plus AI, devices, and workforce trends reshaping care.